View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
 PRESS RELEASE

Press release: Sanofi successfully prices USD 3 billion of bond issue

Press release: Sanofi successfully prices USD 3 billion of bond issue Sanofi successfully prices USD 3 billion of bond issue   Paris, France – October 28, 2025 - Sanofi announces that it has successfully priced its offering of $3 billion of notes across 5 tranches:  $400 million fixed rate notes, due November 2027, bearing interest at a rate of 3.75%. $500 million floating rate notes, due November 2027, bearing interest at compounded SOFR plus 0.46%. $400 million fixed rate notes, due November 2028, bearing interest at a rate of 3.80%. $500 million floating rate notes, due November 202...

 PRESS RELEASE

Communiqué de presse : Sanofi place 3 milliards de dollars d’emprunts ...

Communiqué de presse : Sanofi place 3 milliards de dollars d’emprunts obligataires Sanofi place 3 milliards de dollars d’emprunts obligataires  Paris, 28 Octobre 2025 - Sanofi annonce avoir placé avec succès une émission obligataire en 5 tranches (les « obligations ») pour un montant de 3 milliards de dollars :  400 millions de dollars US d’obligations à taux fixe, échéance novembre 2027 portant intérêt au taux de 3.75% 500 millions de dollars US d’obligations à taux variable, échéance novembre 2027, portant intérêt au taux de SOFR capitalisé + 0.46%400 millions de dollars US d’obligat...

Pfizer Inc.: Update to credit analysis

Our credit view of this issuer reflects its good scale, diversity and pipeline opportunities, weighed against its large patent exposures towards the end of the decade.

Jacob Mekhael
  • Jacob Mekhael

Merus Petosemtamab phase 2 mCRC results show high response rates

Merus announced interim clinical data (29 July 2025 cutoff) from the ongoing phase 2 trial of petosemtamab (EGFR x LGR5 bispecific antibody) + standard of care FOLFOX/FOLFIRI (chemo) in 1L, 2L metastatic CRC (mCRC) and petosemtamab monotherapy in 3L+ mCRC. The results were presented at the AACR-NCI-EORTC, and confirm and build upon the responses reported from an initial dataset with a previous cut-off date (28 April 2025). We view the numbers as competitive vs. cetuximab (EGFR antibody) + FOLFOX...

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thomas Couvreur
Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
 PRESS RELEASE

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer De...

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed)  UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates ...

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
Rafael Bonardell
  • Rafael Bonardell

SANOFI: RDOS. 3T’25 (ANÁLISIS BANCO SABADELL)

Rdos. 3T'25 vs 3T'24: Ventas: 12.434 M euros (-7,5% vs -9,7% BS(e) y -9,0% consenso); EBIT: 4.445 M euros (-3,5% vs -10,3% BS(e) y -10,2% consenso). Rdos. 9meses'25 vs 9meses'24: Ventas: 32.323 M euros (-6,7% vs -7,6% BS(e) y -7,3% consenso); EBIT: 9.808 M euros (-4,4% vs -7,5% BS(e) y -7,4% consenso).

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch